Lonza Signs Manufacturing Agreement with U.S. Biopharma Firm

Lonza says it has entered into a manufacturing services agreement with biopharmaceutical firm Morphotek (Exton, PA), to support the development and manufacturing of a subset of antibodies in Morphotek’s therapeutics pipeline. Lonza will reserve capacity for commercial manufacturing of Morphotek’s lead compound farletuzumab, which recently entered Phase III clinical trials for ovarian cancer, under the deal. Sijbesma: Strength in life sciences units. Morphotek, a subsidiary of pharma company Eisai (Woodcliff Lake, NJ), specializes in the development of...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers